Maharashtra Herald

DelveInsight’s, “Renal Cancer Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Renal Cancer pipeline landscape. It covers the Renal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Renal Cancer Pipeline @ https://www.delveinsight.com/sample-request/renal-cancer-pipeline-insight

Key Takeaways from the Renal Cancer Pipeline Report

• On June 30, 2026- Jonsson Comprehensive Cancer Center conducted a phase I/II trial tests the safety, side effects and effectiveness of radioembolization with yttrium-90 (Y-90) in patients with early stage renal cell carcinoma. Y-90 is a radioactive chemical that is incorporated into millions of very tiny glass spheres. These spheres are injected into the artery that feeds the cancer. This process is called radioembolization. Y-90 radioembolization may be a safe and effective treatment for patients with early stage renal cell carcinoma.
• On June 26, 2026- Merck Sharp & Dohme LLC initiated a phase 3 study is to learn if people who receive belzutifan and zanzalintinib live longer overall and without the cancer getting worse compared to people who receive belzutifan and placebo. A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. Researchers want to learn if adding another targeted therapy called zanzalintinib (another study medicine) can treat more people with advanced RCC than belzutifan alone.
• DelveInsight’s Renal Cancer pipeline report depicts a robust space with 75+ Renal Cancer companies working to develop 80+ pipeline therapies for Renal Cancer treatment.
• The leading Renal Cancer Companies such as Merck, Corvus Pharmaceuticals, Kura Oncology, Bristol-Myers Squibb, HiberCell, Inc, Jiangsu Hansoh Pharmaceutical Co., Ltd., Second Life Therapeutics, Imbioray (Hangzhou) Biomedicine Co., Ltd., Zhejiang Haichang Biotech Co., Ltd., UTC Therapeutics Inc., Neomorph, Inc, Pfizer, Aurigene Discovery Technologies Limited, Xencor, Inc., Nuvectis Pharma, Inc., Antengene Corporation, Zhejiang Doer Biologics, Tempest Therapeutics, Allogene Therapeutics, Janux Therapeutics and others.
• Promising Renal Cancer Pipeline Therapies such as Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, Axitinib, MK-3475, Bevacizumab, Interferon alpha-2a, CP-461, and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Renal Cancer Treatment Drugs

Renal Cancer Overview

Renal cancer, also known as kidney cancer, is a malignant disease that originates in the tissues of the kidneys vital organs responsible for filtering blood, removing waste, and maintaining fluid balance. The most common subtype is Renal cell carcinoma, which accounts for the majority of adult cases. Less frequent forms include Urothelial carcinoma of the renal pelvis, Wilms tumor in children, and rare renal sarcomas. The disease is often asymptomatic in its early stages and is increasingly identified incidentally during imaging performed for unrelated medical evaluations. In its early course, renal cancer may present with subtle or no symptoms, but as it progresses, patients can experience hematuria (blood in the urine), persistent flank or lower back pain, and sometimes a palpable abdominal mass. Systemic manifestations such as unexplained weight loss, fatigue, and intermittent fever may also occur. In advanced stages, symptoms related to metastasis such as bone pain or chronic cough can arise, reflecting disease spread. Features like fever or night sweats without an infectious cause may indicate more advanced or aggressive disease progression.

Renal Cancer Emerging Drugs Profile

• Zanzalintinib: Exelixis

Zanzalintinib (XL092) is an investigational, next-generation oral tyrosine kinase inhibitor being developed by Exelixis for the treatment of renal cell carcinoma (RCC). It targets multiple kinases including VEGFR, MET, and TAM family receptors (AXL, MER), thereby inhibiting tumor angiogenesis, metastasis, and immune evasion. In RCC, zanzalintinib is designed to modulate the tumor microenvironment and enhance responsiveness to immunotherapy. It is being evaluated in combination with agents such as Nivolumab in ongoing clinical trials, including Phase III studies in non-clear cell RCC.

• Quavonlimab: Merck

Quavonlimab in combination with Pembrolizumab is an investigational fixed-dose monoclonal antibody regimen being evaluated for the treatment of renal cell carcinoma (RCC) under the LITESPARK-012 study. Quavonlimab targets CTLA-4, enhancing T-cell activation by blocking inhibitory signaling, while pembrolizumab inhibits the PD-1 pathway to restore anti-tumor immune responses. This dual checkpoint blockade is designed to produce a more robust and sustained immune-mediated attack on tumor cells. The combination aims to improve clinical outcomes, particularly in patients with advanced or treatment-resistant RCC. Quavonlimab is being developed under an agreement with Akeso Inc. and is currently under Phase III of its development.

• Ciforadenant: Corvus Pharmaceuticals

Ciforadenant is an oral, small-molecule antagonist of the adenosine A2A receptor, designed to counteract adenosine-mediated immunosuppression within the tumor microenvironment. By blocking A2A signaling, it enhances the activity of cytotoxic T cells and promotes anti-tumor immune responses. In renal cell carcinoma (RCC), where high adenosine levels contribute to immune evasion, ciforadenant has shown potential to restore immune sensitivity. It is being investigated both as a monotherapy and in combination with immune checkpoint inhibitors, particularly in patients resistant to prior immunotherapies. According to the company’s pipeline, Ciforadenant is currently in Phase II development for Renal Cancer.

• Darlifarnib: Kura Oncology

Darlifarnib (KO-2806) is an investigational, next-generation farnesyl transferase inhibitor (FTI) being evaluated for the treatment of renal cell carcinoma (RCC). In combination with Cabozantinib, a multi-kinase inhibitor targeting VEGFR, MET, and AXL pathways, darlifarnib aims to enhance anti-tumor efficacy by simultaneously disrupting oncogenic signaling and tumor angiogenesis. This combination approach is designed to overcome resistance mechanisms commonly observed with monotherapies in advanced RCC. By targeting complementary pathways, the regimen may provide deeper and more durable clinical responses. The drug is currently in Phase I development for the treatment of Renal cell carcinoma (RCC).

• BMS-986506: Bristol-Myers Squibb

BMS-986506 is an investigational small-molecule therapy being developed by Bristol Myers Squibb for the treatment of advanced renal cell carcinoma (RCC). It is currently being evaluated in a first-in-human Phase I/Ib clinical trial in patients with advanced or metastatic RCC who have progressed on prior therapies. The study focuses on assessing its safety, tolerability, and pharmacokinetic profile as a monotherapy. BMS-986506 remains investigational, and its safety and efficacy are yet to be established. The drug is currently being evaluated in Phase I for the treatment of Renal cell carcinoma (RCC).

• ATG-106: Antengene Corporation

ATG-106 is an investigational bispecific antibody designed to target CDH6 on tumor cells and CD3 on T cells, enabling direct T-cell–mediated killing of cancer cells. By binding CDH6, which is overexpressed in certain ovarian cancers and renal cell carcinoma (kidney cancer), the therapy selectively directs immune activity toward malignant cells. Simultaneous engagement of CD3 activates T cells, promoting cytotoxic responses within the tumor microenvironment. This mechanism aims to enhance anti-tumor efficacy while minimizing off-target effects. The drug is currently in preclinical stage of its development for the treatment of Renal Cancer.

• DR315: Zhejiang Doer Biologics

DR315 is an investigational bispecific antibody drug conjugate (ADC) designed for the treatment of clear cell renal cell carcinoma (RCC). It targets both CA9 and CD70, leveraging their differential expression on tumor versus normal tissues to enhance tumor selectivity and reduce on-target toxicity, particularly hematological effects seen with CD70-directed therapies. DR315 incorporates a novel linker with a topoisomerase inhibitor payload, enabling efficient delivery of cytotoxic activity directly to cancer cells. In preclinical in vitro and in vivo studies, it has demonstrated strong tumor cell killing and anti-tumor efficacy, along with a favorable safety profile in non-human primate studies. DR315 remains investigational, with plans to submit an IND application in 2026.

The Renal Cancer Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Renal Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Renal Cancer Treatment.
• Renal Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Renal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Renal Cancer market

Explore groundbreaking therapies and clinical trials in the Renal Cancer Pipeline @ New Renal Cancer Drugs

Renal Cancer Companies

Merck, Corvus Pharmaceuticals, Kura Oncology, Bristol-Myers Squibb, HiberCell, Inc, Jiangsu Hansoh Pharmaceutical Co., Ltd., Second Life Therapeutics, Imbioray (Hangzhou) Biomedicine Co., Ltd., Zhejiang Haichang Biotech Co., Ltd., UTC Therapeutics Inc., Neomorph, Inc, Pfizer, Aurigene Discovery Technologies Limited, Xencor, Inc., Nuvectis Pharma, Inc., Antengene Corporation, Zhejiang Doer Biologics, Tempest Therapeutics, Allogene Therapeutics, Janux Therapeutics and others.

Renal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Renal Cancer Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Renal Cancer Market Drivers and Barriers

Scope of the Renal Cancer Pipeline Report

• Coverage- Global
• Renal Cancer Companies- Merck, Corvus Pharmaceuticals, Kura Oncology, Bristol-Myers Squibb, HiberCell, Inc, Jiangsu Hansoh Pharmaceutical Co., Ltd., Second Life Therapeutics, Imbioray (Hangzhou) Biomedicine Co., Ltd., Zhejiang Haichang Biotech Co., Ltd., UTC Therapeutics Inc., Neomorph, Inc, Pfizer, Aurigene Discovery Technologies Limited, Xencor, Inc., Nuvectis Pharma, Inc., Antengene Corporation, Zhejiang Doer Biologics, Tempest Therapeutics, Allogene Therapeutics, Janux Therapeutics and others.
• Renal Cancer Pipeline Therapies- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, Axitinib, MK-3475, Bevacizumab, Interferon alpha-2a, CP-461, and others.
• Renal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Renal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth pipeline report today! @ Renal Cancer Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Renal Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Renal Cancer – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Zanzalintinib: Exelixis
9. Mid Stage Products (Phase II)
10. Ciforadenant: Corvus Pharmaceuticals
11. Early Stage Products (Phase I)
12. BMS-986506: Bristol-Myers Squibb
13. Preclinical Stage Products
14. ATG 106: Antengene Corporation
15. Discovery Stage Products
16. TPST-3206: Tempest Therapeutics
17. Inactive Products
18. Renal Cancer Key Companies
19. Renal Cancer Key Products
20. Renal Cancer – Unmet Needs
21. Renal Cancer – Market Drivers and Barriers
22. Renal Cancer – Future Perspectives and Conclusion
23. Renal Cancer Analyst Views
24. Renal Cancer Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/renal-cancer-pipeline-insight